ASCO 2023

CDK4/6i in EBC: Have abema and ribo arrived in the…

ADC revolution: How can the new results be integrated…

Sonia trial: How does the new data change clinical…

PART2: Trying to understand optimal therapy for…

PART1: How to de-escalate chemotherapy? What is the…

CDK4/6 inhibitors in EBC: Amazing data, but longer…

Data from Meta-Analyses of almost 15k Patients: Who…

Chemotherapy de-escalation in HER2+ patients:…

Tumor-informed ctDNA likely prognostic for relapse in…

More CDK4/6 options for EBC patients

A challenge for clinical management

Can we preserve our patients form chemotherapy?

My EBC highlights from ASCO23

Ovarian function - Ovarian suppression not necessary in…

Young patients benefit from ovarian suppression

Another proof of efficacy of immunotherapy in advanced…

First data with adjuvant ribociclib

10 years update on ShortHER

TILs subtypes are associated with clinical features and…

Chemo-immunotherapeutic signals especially in HER2low…

Discussions on CDK4/6 inhibitors in EBC

Response adapted, chemotherapy-free option in HER2+ EBC

Palbociclib after Palbociclib might not be the best…

1/3 of patients with HER2+ in future without…

SOC of ovarian ablation confirmed in meta-analysis.

TILs are prognostic but not predictive in HER2+ EBC

De-escalation of CT for early BC

Checkpoint inhibition in endometrial cancer: new…

Early follow-up shows clear benefit

Analyses of ctDNA in PENELOPE-B: Test methods are…

Ribociclib improves iDFS

TILs in HER2+ disease - prognostic, but not enough to…

Practice changing or not quite yet?

PHERGain opens the possibility to avoid chemotherapy in…

From PENELOPE-B to SURVIVE

White blood cells with increasing prognostic relevance?…

Eine Herausforderung für viele Patienten, wenig…

Tumor-informed ctDNA wahrscheinlich prognostisch für…

Eine Herausforderung für das klinische Management

Primele date cu ribociclib adjuvant

1/3 der Patientinnen mit HER2+ zukünftig ohne…

SOC der ovarialen Ablation in der Metaanalyse bestätigt

PHERGain abre la posibilidad de evitar la quimioterapia…

I miei punti salienti di ASCO23

TILs w rakach HER2+ - znaczenie rokownicze, ale nie…

Palbociclib después de Palbociclib podría no ser la…

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

Czy wystarczy, aby zmienić standardy?

NATALEE nicht überraschend aber überzeugend positiv

Response adaptierte, Chemotherapie-freie Option beim…

Von PENELOPE-B zur SURVIVE

Kolejny dowód na skuteczność immunoterapii w…

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

Ovar Funktion - Ovarielle Supression verzichtbar bei…

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

The start of precision medicine in HR+ breast cancer

What is the optimal therapie sequence for HR+ MBC…

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

E-Health Applications in Oral Cancer Therapy

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo…

Mises à jour sur les ADC dans le cancer du sein…

CDK4/6i in first line and beyond & Biomarkers

CDK4/6 Sequencing? ESR-1 not ready for prime time?…

The value of eHealth

ARASEC: ADT + Daralutamide for mHSPC

DEAR trial: real-world comparator analyses of ARIs

Confirming results for PARPi in mCRPC

Intensified or de-intensified therapy in mHSPC

Part 1: Important update on testosterone-recovery

Over-staging of bone scan compared with PSMA PET/CT

PEACE 1 - results and controversies

Part2: Important update on testosterone-recovery

TALAPRO-2: Results and controversies

Metastasis-directed for prostate cancer

PAPR-inhibitors: Patient-selection matters!

AI for prediction in local prostate carcinoma

PSA nadir 6 month after Radiotherapy is strong…

Reassuring real-world data!

LuPARP combination study: LuPSMA and Olaparib in mCRPC

PSA nadir 6 månader efter radioterapi är en prognostisk…

PARP-inhibitors: La selección de pacientes es…

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Triple therapy in mCSPC - which is the ideal partner…

What is your preferred sequence in 1st line treatment…

The beginning of a new era in urothelial cancer?!

Q-TWiST in the therapy of aUC

New SoC option for metastatic bladder cancer

New standard for MIBC

Targeted therapies in advanced urothelial cancer: The…

Enfortumab vedotin + pembrolizumab 1stL in…

Extent of lymphadenectomy in cystectomy

FGFR inhibition

First line in cisplatin-ineligible advance urothelial…

Nouvelles options de soins standard pour le cancer de…

Primera línea en cáncer urotelial avanzado no elegible…

Best of Bladder: ddMVC increases DFS! Standard…

The efficacy of FGFR targeting

Update EV/Pembro, Avelumab Maintenance

Primary endpoint not reached: what do we learn from…

Non ccRCC: how should we treat patients today?

Long term follow up in advanced renal cell cancer: Is…

News from the adjuvant

IO rechallenge in mRCC

Update and take home message of 1st Line mRCC

Long-term follow-up for IO/TKI in mRCC

1st Line therapy RCC: which combination to choose?

Lenvatinib + pembrolizumab in non-clear cell renal cell…

New standard for 2nd line RCC?

The value of perioperative chemo-IO in rNSCLC and the…

More options in the perioperative setting

ADAURA - results and controversies

Another neoadjuvant chemo/IO option

A new standard of care

EGFR testing necessary in the adjuvant setting

Which should we prefer: neoadjuvant, adjuvant or…

CheckMate 9LA: 4‑year clinical update

Perioperative treatment

Role of periopertative IO confirmed

Induction options in the perioperative setting

Adjuvant and neoadjuvant strategies in resectable NSCLC

An imperfect analysis, but perfect results

A chemo-free preop. IO strategy?

Added benefit of perioperative chemo/IO in stage 2-3b…

ADAURA - Discussion closed?

A new standard of care for operated patients with…

Confirmation of neoadjuvant immunotherapy

OS benefit from EGFR receptor TKI

ADAURA- discussie gesloten?

Un nouveau standard therapeutique pour les patients…

Más opciones en el entorno perioperatorio

Rolle der periopertativen IO bestätigt

Stratégies adjuvantes et néoadjuvantes dans le CBNPC…

Que devrions-nous préférer: traitement néoadjuvant,…

Pembro + chemo in pts with TKI-resistant EGFRm /…

TTF-treatment requires further studies

Update on KRASG12Cm treatment options - how to proceed?

Sotorasib: clear clinical benefit, but short follow-up…

Does ADC + chemo + IO replace the existing concepts?

TROP2-ADC shows high response rates in 1L-combination…

IO in EGRF positive patients post TKI

Stopping treatment is ok

CORRELATE - a real world analysis

LUNAR: TTF medical device shows OS-benefit, but more…

New data from another BiTE

Can we incoporate biomarkers in SCLC treatment?

More BiTEs, more possibilities

Hyperfractionated radiotherapy for SCLC

A positive trial with no impact

Stratégies de traitement dans le SCLC

Kunnen we biomarkers gebruiken om behandeling te…

ONCOalert (inclusive patient advocates) consensus on…

Immune checkpoint inhibitors in malignant mesothelioma